To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic (Coronavirus19)

The COVID-19 pandemic might be an opportunity to review and refine our practices in anti TB treatment. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective. The aim of the study is to assess the efficiency and the satisfaction with telephone consultation for the pharmacist and the TB patient. The study was conducted in tertiary care hospital TB control centres patients.

Study Overview

• Status: Unknown
• Conditions: Patient Satisfaction; TB - Tuberculosis
• Intervention / Treatment: Behavioral: Patient-centred advice on Telephone Consultation in TB Patients:

Detailed Description

Tuberculosis (TB) is the world's biggest killer among infectious diseases, claiming more than 4000 lives each day. The unprecedented coronavirus pandemic seriously impacts people with pre-existing health conditions. People who have TB are usually more vulnerable to other infections, including the novel coronavirus, due to pre-existing lung damage. They are at a higher risk of developing complications from COVID-19. Certain populations are at greater risk of TB, because of where they live, where they work or because of other socio-economic factors which result in them experiencing barriers to accessing health services.

• Study Type: Interventional
• Enrollment (Anticipated): 200
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Pakistan
  • KPK
    • Bannu, KPK, Pakistan, 2800
      • Recruiting
      • Dhq Bannu Kpk
      • Contact: Farman Ull ah Khan; Phone Number: +92331-3319443131; Email: farmankhan@bs.qau.pk
    • Bannu, KPK, Pakistan, 2800
      • Recruiting
      • District Bannu TB Control Center
      • Contact: Asif Ul Khan, Master; Phone Number: 0092334087008; Email: asifkhanustb@gmail.com
      • Principal Investigator: Farman Ul Khan, Master
      • Sub-Investigator: Yu Fang, Phd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

New, smear-positive drug-susceptible TB who have been on treatment for less than two weeks Access to a mobile phone (self-reported)

Exclusion Criteria:

Patients who do not have regular access to a mobile phone Patients who have previously received TB treatment Patients who have another member in their household who is already a part of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Telephone Consultation in TB Patients; The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost-effective.	Behavioral: Patient-centred advice on Telephone Consultation in TB Patients: The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficiency of the telephone consultation,	To improve patient centered care/patient prescription refill	2 Months
Patient satisfaction	Patient satisfaction Patient satisfaction resulting from pharmacist-led pharmaceutical care will be assessed Patient satisfaction feedback (PSF)	2 Month

Secondary Outcome Measures

Outcome Measure	Time Frame
Adherence Rate	2 Months

Collaborators and Investigators

• Sponsor: Health Science Center of Xi'an Jiaotong University
• Collaborators: Pakistan Institute of Medical Sciences Islamabad Pakistan; District Headquarter Hospital Bannu Pakistan

Study record dates

Study Major Dates

• Study Start (Actual): April 20, 2020
• Primary Completion (Anticipated): December 20, 2020
• Study Completion (Anticipated): December 20, 2020

Study Registration Dates

• First Submitted: May 30, 2020
• First Submitted That Met QC Criteria: May 30, 2020
• First Posted (Actual): June 2, 2020

Study Record Updates

• Last Update Posted (Actual): November 18, 2020
• Last Update Submitted That Met QC Criteria: November 16, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Actinomycetales Infections; Mycobacterium Infections; COVID-19; Tuberculosis
• Other Study ID Numbers: NO, F6-2017/NTP-ADMIN

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No